Ignite Creation Date:
2024-05-05 @ 11:54 PM
Last Modification Date:
2024-10-26 @ 10:41 AM
Study NCT ID:
NCT01449461
Status:
COMPLETED
Last Update Posted:
2021-08-17
First Post:
2011-09-30
Brief Title:
A Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase ALKEpidermal Growth Factor Receptor EGFR Inhibitor Brigatinib AP26113
Sponsor:
Organization:
Takeda